Is Quintiles plotting a $3B IPO?

Those Quintiles IPO murmurs from last fall are ramping up again, but this time the rumors have teeth. Both Bloomberg and Reuters report that the CRO giant's private equity masters are actively interviewing banks to handle a Wall Street debut. Bain Capital and TPG Capital, Quintiles' lead investors, have talked to JPMorgan Chase, Deutsche Bank and others, the news agencies report--citing anonymous sources, of course. The potential IPO could price north of $3 billion, analysts estimate, and Bloomberg's "people with knowledge of the matter" say we can expect the CRO to go public later this year. Report


Suggested Articles

Monoclonal antibodies developer Xencor extended a strategic alliance formed in 2016 with Selexis with four commercial license agreements.

Raxone is currently in a phase 3 study on DMD patients who are taking glucocorticoids.

The SuperHuman library contains over 5,000 hits against each of the 26 Distributed Bio targets in immunology and neurodegeneration.